Tag: Cobenfy

For decades, negative symptoms in schizophrenia have been notoriously difficult to treat, with traditional antipsychotics primarily targeting positive symptoms. A major development in this field is the FDA approval of Cobenfy (KarXT) in 2024, raising the question: what is the new antipsychotic for negative symptoms and how does it work differently?.

In September 2024, the FDA approved the first new class of antipsychotic medications in decades, containing the active muscarinic agonist **xanomeline**. This oral medication, marketed as Cobenfy, represents a significant paradigm shift by targeting cholinergic receptors to treat schizophrenia in adults.

Affecting about 1% of the population, schizophrenia has been treated largely with dopamine-targeting medications for decades. The recent FDA approval of **COBENFY**, a new schizophrenia drug, marks a significant shift with its novel, non-dopamine mechanism of action. This first-in-class muscarinic agonist represents a new pharmacological approach to managing schizophrenia symptoms in adults.

Recent research indicates that schizophrenia spectrum disorders are more common than previously thought, affecting approximately 1.8% of U.S. adults [1.8.1]. For them, the critical question is often, **what is the new drug for schizophrenia?** The latest answer marks a significant breakthrough in treatment.